Multi-omics analyses and integration of NCI-cptac-relevant cancer sample
Ended Awarded Last action
- Contract number
- 75N91018F00063
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,063,018
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $3,063,018.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $36,460 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $3,026,558 |
About this award
This is a federal contract awarded by the Department of Health and Human Services' (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for "Multi-Omics Analyses and Integration of NCI-CPTAC-Relevant Cancer Sample" and has a potential value of $3,063,018.00. It was awarded on a cost-plus-fixed-fee basis and does not have a set-aside designation.
Leidos Biomedical Research, as an NCI Federally Funded Research and Development Center (FFRDC) contractor, provides a broad range of biomedical research and facilities support services to the NCI. This contract is likely a task order issued under the FFRDC contract, which has a potential value of $6.6 billion over five years. The work involves multi-omics analyses and integration of cancer samples relevant to the NCI's Clinical Proteomic Tumor Analysis Consortium (CPTAC) program, which focuses on advanced cancer proteogenomic research. Leidos Biomedical Research has extensive experience supporting federal biomedical research efforts, including work in areas like cancer, HIV/AIDS, influenza, COVID-19, and gene therapy. The contract also includes a $49,700 subcontract with Thermo Electron North America LLC for the procurement of specialized capital equipment to support the research.
Quick answers
Who was awarded contract 75N91018F00063?
75N91018F00063 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 24, 2018.
How much is contract 75N91018F00063 worth?
The government has obligated $3,063,018 on 75N91018F00063.
Is contract 75N91018F00063 an order under another contract?
Yes. 75N91018F00063 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract 75N91018F00063 competed?
The extent of competition for 75N91018F00063 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award